Immuno-Oncology for Gynecologic Malignancies

Area of Science:

• Gynecologic Oncology
• Immunotherapy
• Cancer Research

Background:

• Current cytotoxic and targeted therapies offer limited benefits for advanced/recurrent gynecologic cancers.
• Successful immunotherapy in other cancers motivates its investigation in gynecologic malignancies.
• Approved immunotherapies are restricted to specific molecular subtypes (MSI-high, TMB-high) and PD-L1-positive cervical cancer.

Purpose of the Study:

• To review major reported and ongoing immunotherapy clinical trials in gynecologic cancers.
• To highlight the growing interest and investment in immunotherapy for these diseases.

Main Methods:

• Review of published data and ongoing clinical trial information.
• Focus on immunotherapy approaches alone and in combination with other treatments.
• Specific examination of trials in endometrial, cervical, and epithelial ovarian cancer.

Main Results:

• Significant growth in clinical trials testing immunotherapy in gynecologic cancers.
• Exploration of immunotherapy in combination with chemotherapy and targeted agents.
• Limited but expanding FDA-approved uses of immune checkpoint inhibitors.

Conclusions:

• Immunotherapy represents a promising frontier for treating gynecologic cancers.
• Ongoing clinical trials are crucial for establishing the efficacy and safety of these novel treatments.
• Further research is needed to expand immunotherapy options for a broader range of patients.